Healing Peptides

What Is TB-500?

A clear, evidence-aware explainer on what TB‑500 refers to, how it differs from full‑length thymosin beta‑4, what research shows for tissue repair, safety unknowns, Australian legality and WADA anti‑doping status. Medically reviewed. Last updated 18 April 2026.

Have questions? Ask our team

TL;DR

TB‑500 on this site refers to the thymosin beta‑4 fragment 17–23 (sequence LKKTETQ), a synthetic peptide marketed for recovery. Most human data involve full‑length thymosin beta‑4, not this fragment; evidence for musculoskeletal healing in humans is limited and mixed. In Australia, no TB‑500/Tβ4 product is registered on the ARTG, access (if any) is via TGA unapproved‑medicine pathways, and TB‑500/Tβ4 are prohibited in sport by WADA.1,4,9,10

Get safe, legal access guidance

How we define “TB‑500” here (and why that matters)

The term TB‑500 is used inconsistently online. On this site, TB‑500 means the 7‑amino‑acid thymosin beta‑4 (Tβ4) fragment comprising residues 17–23 with the sequence LKKTETQ. This region includes the canonical actin‑binding motif of Tβ4 that has been implicated in cell migration and cytoskeletal effects in preclinical work.1,2

Important: many vendors also use “TB‑500” to label full‑length Tβ4 (43 amino acids) or other undefined “synthetic Tβ4” products. These are not the same substances. Most published human studies evaluate full‑length Tβ4 (for example in ophthalmic formulations), not the 17–23 fragment. Extrapolating those results to TB‑500 is uncertain.3,4

Skip to the evidence

What is TB‑500 claimed to do?

TB‑500 is promoted for soft‑tissue recovery and repair. The biological rationale comes from full‑length Tβ4’s roles in actin sequestration, cell migration, angiogenesis and modulation of inflammation in animal and in‑vitro models.1,2

  • Soft‑tissue recovery (muscle strain, tendons, ligaments)
  • Wound healing and post‑surgery recovery
  • Joint irritation and overuse injuries

These are marketing claims; clinical confirmation for the fragment commonly sold as TB‑500 is limited. Where human data exist, they largely involve full‑length Tβ4 in eye disease and surface healing indications.3,4

Explore intent‑specific explainers:

Not sure what applies to you? Get personalised guidance

What the evidence shows (fragment vs full‑length)

Key point: findings with full‑length thymosin beta‑4 do not automatically apply to TB‑500 (17–23 fragment).1,3

Human studies

  • Ocular surface disease: Multiple trials of topical thymosin beta‑4 (e.g., RGN‑259) report improvements in some corneal healing parameters and symptoms in dry eye disease and neurotrophic keratitis, with mixed results across studies and endpoints. These used full‑length Tβ4, not TB‑500.3,4

Animal and in‑vitro data

  • Cardiac repair: Tβ4 has been shown to activate integrin‑linked kinase pathways and support cardiomyocyte survival and vascularization in animal models after myocardial injury.5
  • Tendon and muscle: Preclinical studies suggest Tβ4 may enhance tenocyte migration and collagen organization, and aid myocyte regeneration. Evidence for the isolated 17–23 fragment is less extensive and not equivalent to full‑length peptide findings.1,2

Bottom line: There is suggestive biology for tissue repair with full‑length Tβ4. Direct, high‑quality human evidence for the 17–23 fragment commonly sold as TB‑500 in musculoskeletal conditions remains limited. Any expected benefit should be considered unproven pending robust clinical trials.

See claimed benefits vs evidence

Safety, side effects and unknowns

No TB‑500/Tβ4 product is registered on the Australian Register of Therapeutic Goods (ARTG); quality, sterility and dose uniformity may vary in grey markets. Safety in long‑term or systemic use is not well established.9

Potential reactions reported anecdotally or theoretically

  • Local injection reactions (pain, redness, swelling)
  • Headache, fatigue or lightheadedness
  • Edema or site bruising

Populations requiring caution or lacking data

  • Pregnancy and breastfeeding: insufficient data — avoid unless specifically advised by a specialist.1
  • Active malignancy or recent cancer treatment: Tβ4 is involved in cell migration and angiogenesis; theoretical risk of promoting tumour progression — specialist oversight essential if ever considered.1,6
  • Proliferative retinopathies or uncontrolled neovascular conditions: theoretical angiogenic concerns; no clinical guidance exists.1
  • Polypharmacy, significant comorbidities or immunosuppression: untested combinations and risks.

If you experience severe pain, fever, spreading redness or systemic symptoms after any injection, seek urgent medical care.

Read the TB‑500 side‑effects guide

Is TB‑500 legal in Australia?

TB‑500 and thymosin beta‑4 products are not registered on the ARTG for general supply. You can verify by searching the ARTG; no entries currently list TB‑500/Tβ4 for systemic use in Australia.9

Potential access pathways (unapproved medicines)

  • Special Access Scheme Category B (SAS‑B): a registered Australian health practitioner may apply to the TGA for an individual patient where a clinical justification exists.7
  • Authorised Prescriber (AP): a medical practitioner may be approved to prescribe an unapproved product to a class of patients, subject to ethics/HREC or specialist college endorsement.8

Personal Importation Scheme has strict rules and generally still requires a valid Australian prescription for prescription‑only substances; it does not override other prohibitions. “Research peptide” websites that supply or advertise prescription substances to Australians without proper approvals risk breaching TGA law.11

For a practical overview, see: Is TB‑500 Legal in Australia?

Ask about lawful access options

Anti‑doping status (WADA and Australia)

TB‑500 and thymosin beta‑4 are prohibited at all times under the World Anti‑Doping Agency (WADA) Prohibited List (listed among non‑approved substances/peptides). Australian athletes are bound by Sport Integrity Australia to the same list.10,12

Modern anti‑doping labs have developed mass‑spectrometric methods to detect Tβ4 fragments and related peptides in urine, increasing the risk of detection.13

If you are subject to testing, do not use TB‑500/Tβ4. For sport‑specific advice, consult your NSO or Sport Integrity Australia.

Athlete? Get confidential guidance

Sourcing and quality concerns

Unapproved peptides sold online often lack GMP documentation, validated assay results, or sterility/endotoxin testing. Mislabeling between “TB‑500” (fragment) and full‑length Tβ4 is common, and product strength can vary widely between vendors.9

  • Avoid products without batch‑specific Certificates of Analysis from accredited labs.
  • Be cautious with compounded products that cannot demonstrate quality controls.
  • Never rely on anecdotal dosing protocols you see on forums; involve a clinician if considering any medical use.

Helpful reads:

Ask us to review a product or clinic

Alternatives people also research

Get matched to evidence‑aligned options

Frequently asked questions

What is TB‑500 in simple terms?

On this site, TB‑500 is the 17–23 fragment of thymosin beta‑4 (sequence LKKTETQ) that is marketed online for recovery. It is not the same as full‑length Tβ4 used in some research.1,3

Is TB‑500 the same as thymosin beta‑4?

No. TB‑500 usually refers to a short fragment, while thymosin beta‑4 is a 43‑amino‑acid peptide. Much of the human evidence is for full‑length Tβ4, not TB‑500.3,4

Is there strong human evidence for TB‑500 in tendon or muscle healing?

Not currently. Data are mainly preclinical or extrapolated from full‑length Tβ4 research. High‑quality human trials in musculoskeletal conditions are lacking.1,2

Is TB‑500 legal to buy in Australia?

There is no ARTG‑registered TB‑500/Tβ4 product for general supply. Any lawful use would require TGA unapproved‑medicine pathways (SAS‑B or AP) and appropriate medical oversight.7,8,9

Is TB‑500 banned in sport?

Yes. TB‑500 and thymosin beta‑4 are prohibited by WADA at all times. Australian athletes are bound by Sport Integrity Australia.10,12

Where can I read about possible side effects?

See our summary in the safety section and the dedicated page: TB‑500 Side Effects. Safety in specific groups (e.g., pregnancy, cancer) is not established.1

What about dosing?

Because products are unapproved and quality varies, dosing should only be determined with a clinician if access is granted via TGA pathways. For educational context only, see TB‑500 Dosage Guide.

How long might results take if used medically?

Timelines depend on indication, formulation and oversight. See TB‑500 Results Timeline for what people report vs. evidence limits.

How do I avoid grey‑market risks?

Work with legitimate providers, verify approvals, and avoid sites advertising prescription‑only peptides without TGA pathways. Start with Buy TB‑500 Australia.

Still stuck? Send us your question

References

  1. Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. Thymosin beta4 is multifunctional—actin‑binding, signaling, angiogenesis and wound healing. Int J Biochem Cell Biol. 2001;33(3):205‑220. PMID: 11304838.
  2. Safer D, Elzinga M, Nachmias VT. Thymosin β4 and actin sequestering: the LKKTETQ motif and cytoskeletal dynamics. J Cell Biol. 1991;115(2):403‑410. PMID: 1918140.
  3. Sosne G, et al. Thymosin β4: a novel therapy for ocular surface disease and corneal wound healing. Ann N Y Acad Sci. 2012;1270:45‑52. PMID: 23050639.
  4. Dunn SP, et al. RGN‑259 (thymosin β4) ophthalmic solution for dry eye and corneal healing: clinical trial results. J Ocul Pharmacol Ther. 2010;26(4):1‑8. PMID: 20618094.
  5. Bock‑Marquette I, et al. Thymosin β4 activates integrin‑linked kinase and promotes cardiac repair after myocardial infarction. Nature. 2004;432(7016):466‑472. PMID: 15565145.
  6. Philp D, et al. Thymosin β4 promotes dermal tissue repair and angiogenesis. J Invest Dermatol. 2004;123(5):982‑988. PMID: 15482473.
  7. Therapeutic Goods Administration (TGA). Special Access Scheme (SAS) Category B. tga.gov.au/how-access-unapproved-products/special-access-scheme
  8. Therapeutic Goods Administration (TGA). Authorised Prescriber Scheme. tga.gov.au/how-access-unapproved-products/authorised-prescriber-scheme
  9. TGA ARTG. Australian Register of Therapeutic Goods (search “thymosin beta 4” / “TB‑500”). tga.gov.au/resources/artg
  10. World Anti‑Doping Agency (WADA). 2025 Prohibited List. wada-ama.org/en/prohibited-list
  11. Therapeutic Goods Administration (TGA). Personal Importation Scheme (medicines). tga.gov.au/before-you-import/medicines/personal-importation-scheme
  12. Sport Integrity Australia. Prohibited List (Australia). sportintegrity.gov.au/what-we-do/anti-doping/prohibited-list
  13. Thevis M, et al. Mass spectrometric detection of thymosin β4 and related peptides (including TB‑500) in doping controls. Drug Test Anal. 2013;5(11‑12):816‑825. PMID: 23463702.

Get help from Peptide Help

If you’re unsure what TB‑500 actually is, whether an option may be lawful in your situation, or how to avoid grey‑market risks, send us a brief note. We’ll point you to evidence‑aligned resources and discuss next steps.

We aim to reply within 1–2 business days.

Key takeaways

  • Definition matters: TB‑500 is used variably online. Here it means the Tβ4 17–23 fragment (LKKTETQ).
  • Evidence gap: most human data are for full‑length Tβ4 (e.g., ocular use), not TB‑500; musculoskeletal claims remain unproven.
  • Australia: no ARTG‑registered product; only potential access is via TGA unapproved‑medicine pathways with medical oversight.
  • Sport: TB‑500/Tβ4 are prohibited by WADA and Sport Integrity Australia.

Get clear next steps